Literature DB >> 23643485

Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice.

Tina Löffler1, Stefanie Flunkert, Daniel Havas, Miklós Sántha, Birgit Hutter-Paier, Ernst Steyrer, Manfred Windisch.   

Abstract

During their lifetime, people are commonly exposed to several vascular risk factors that may affect brain ageing and cognitive function. In the last few years, increasing evidence suggests that pathological plasma lipid profiles contribute to the pathogenesis of late-onset Alzheimer's disease. Importantly, hypercholesterolemia, especially elevated low-density lipoprotein cholesterol values, that is, increased apolipoprotein B-100 (ApoB-100) levels, represents an independent risk factor. In this study, the effects of ApoB-100 overexpression, either alone or in combination with cerebral expression of human amyloid precursor protein (hAPP), on cognitive functions and brain pathology were assessed. Our results show that ApoB-100 overexpression induces memory decline and increases cerebral lipid peroxidation and amyloid beta levels compared to those in wild-type animals. Although double-transgenic ApoBxAPP animals did not develop more distinct behavioral deficits than single-transgenic hAPP littermates, hApoB-100 expression caused additional pathophysiological features, such as high LDL and low HDL-cholesterol levels, increased lipid peroxidation, and pronounced ApoB-100 accumulation in cerebral vessels. Thus, our results indicate that ApoBxAPP mice might better reflect the situation of elderly humans than hAPPsl overexpression alone.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Apolipoprotein B-100; Brain; Hyperlipidemia; Transgenic mice; Vascular risk factor

Mesh:

Substances:

Year:  2013        PMID: 23643485     DOI: 10.1016/j.neurobiolaging.2013.04.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  13 in total

1.  Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB.

Authors:  Thomas S Wingo; David J Cutler; Aliza P Wingo; Ngoc-Anh Le; Gil D Rabinovici; Bruce L Miller; James J Lah; Allan I Levey
Journal:  JAMA Neurol       Date:  2019-07-01       Impact factor: 18.302

2.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

3.  The Effect of Nutrients on Alzheimer's Disease Biomarkers: A Metabolomic Approach.

Authors:  Εfstathia G Kalli
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer's disease.

Authors:  Xuesong Chen; Liang Hui; Jonathan D Geiger
Journal:  J Neurol Neurophysiol       Date:  2014-10-01

5.  Cultured cells of the blood-brain barrier from apolipoprotein B-100 transgenic mice: effects of oxidized low-density lipoprotein treatment.

Authors:  Nikolett Lénárt; Fruzsina R Walter; Alexandra Bocsik; Petra Sántha; Melinda E Tóth; András Harazin; Andrea E Tóth; Csaba Vizler; Zsolt Török; Ana-Maria Pilbat; László Vígh; László G Puskás; Miklós Sántha; Mária A Deli
Journal:  Fluids Barriers CNS       Date:  2015-07-17

6.  Serum ApoB levels in depressive patients: associated with cognitive deficits.

Authors:  Li Hui; Mei Han; Xiang Dong Du; Bao Hua Zhang; Shu Chang He; Tian Nan Shao; Guang Zhong Yin
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

7.  Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer's disease and related murine models.

Authors:  Joerg Neddens; Magdalena Daurer; Stefanie Flunkert; Kerstin Beutl; Tina Loeffler; Lauren Walker; Johannes Attems; Birgit Hutter-Paier
Journal:  PLoS One       Date:  2020-07-09       Impact factor: 3.240

8.  Cerebrovascular Pathology in Hypertriglyceridemic APOB-100 Transgenic Mice.

Authors:  Zsófia Hoyk; Melinda E Tóth; Nikolett Lénárt; Dóra Nagy; Brigitta Dukay; Alexandra Csefová; Ágnes Zvara; György Seprényi; András Kincses; Fruzsina R Walter; Szilvia Veszelka; Judit Vígh; Beáta Barabási; András Harazin; Ágnes Kittel; László G Puskás; Botond Penke; László Vígh; Mária A Deli; Miklós Sántha
Journal:  Front Cell Neurosci       Date:  2018-10-25       Impact factor: 5.505

9.  Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease.

Authors:  Tina Löffler; Stefanie Flunkert; Daniel Havas; Cornelia Schweinzer; Marni Uger; Manfred Windisch; Ernst Steyrer; Birgit Hutter-Paier
Journal:  J Neuroinflammation       Date:  2014-05-01       Impact factor: 8.322

10.  Decreased plasma C-reactive protein levels in APOE ε4 allele carriers.

Authors:  Henna Martiskainen; Mari Takalo; Alina Solomon; Alena Stančáková; Mikael Marttinen; Teemu Natunen; Annakaisa Haapasalo; Sanna-Kaisa Herukka; Johanna Kuusisto; Hilkka Soininen; Miia Kivipelto; Markku Laakso; Mikko Hiltunen
Journal:  Ann Clin Transl Neurol       Date:  2018-09-17       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.